The estimated Net Worth of David R. Mc Avoy is at least $303 mil dollars as of 23 July 2021. Mr. Avoy owns over 18,124 units of Brickell Biotech Inc stock worth over $302,866 and over the last 6 years he sold BBI stock worth over $0. In addition, he makes $0 as Chief Compliance Officer, General Counsel, e Assistant Secretary at Brickell Biotech Inc.
David has made over 5 trades of the Brickell Biotech Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 18,124 units of BBI stock worth $12,143 on 23 July 2021.
The largest trade he's ever made was buying 30,435 units of Brickell Biotech Inc stock on 22 June 2020 worth over $71,522. On average, David trades about 11,153 units every 36 days since 2018. As of 23 July 2021 he still owns at least 128,879 units of Brickell Biotech Inc stock.
You can see the complete history of Mr. Avoy stock trades at the bottom of the page.
David R. McAvoy is Chief Compliance Officer, General Counsel, Assistant Secretary of the Company. Mr. McAvoy has served as Brickell’s General Counsel, Chief Compliance Officer and Assistant Secretary since 2019. He previously served as General Counsel, Vice President and Chief Compliance Officer for Endocyte, Inc., a nuclear medicine and oncology biotech, from 2017 to 2018. Prior to joining Endocyte Inc., Mr. McAvoy was at Eli Lilly and Company for 27 years serving in various leadership positions, including as General Counsel of Lilly Emerging Markets, and most recently, in an executive management business role running strategic alliances for the food animal production group at Lilly’s former Elanco Animal Health subsidiary. While at Eli Lilly and Company, Mr. McAvoy was lead FDA counsel launching several medicines, including Prozac® for depression, Gemzar® for pancreatic and lung cancers, and ReoPro®, one of the first interventional cardiology agents. Mr. McAvoy earned a J.D. and M.S. in environmental science from Indiana University and a B.A. in political science from the University of Notre Dame. He serves on the board of directors for The Villages of Indiana, Inc., championing families for abandoned and abused children.
David McAvoy is 57, he's been the Chief Compliance Officer, General Counsel, e Assistant Secretary of Brickell Biotech Inc since 2019. There are 11 older and 6 younger executives at Brickell Biotech Inc. The oldest executive at Brickell Biotech Inc is Albert Nicholas Marchio II, 69, who is the Chief Financial Officer.
David's mailing address filed with the SEC is C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A STREET, TEL AVIV, L3, 6944020.
Over the last 5 years, insiders at Brickell Biotech Inc have traded over $0 worth of Brickell Biotech Inc stock and bought 584,350 units worth $353,337 . The most active insiders traders include Vijay B Samant, Monica E. Luchi, eGary A Lyons. On average, Brickell Biotech Inc executives and independent directors trade stock every 16 days with the average trade being worth of $51,782. The most recent stock trade was executed by Reginald L Hardy on 23 July 2021, trading 200,000 units of BBI stock currently worth $134,000.
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell's executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell's strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs.
Brickell Biotech Inc executives and other stock owners filed with the SEC include: